Emergent high fatality lung disease in systemic juvenile arthritis
Vivian E Saper,Guangbo Chen,Gail H Deutsch,R Paul Guillerman,Johannes Birgmeier,Karthik Jagadeesh,Scott Canna,Grant Schulert,Robin Deterding,Jianpeng Xu,Ann N Leung,Layla Bouzoubaa,Khalid Abulaban,Kevin Baszis,Edward M Behrens,James Birmingham,Alicia Casey,Michal Cidon,Randy Q Cron,Aliva De,Fabrizio De Benedetti,Ian Ferguson,Martha P Fishman,Steven I Goodman,T Brent Graham,Alexei A Grom,Kathleen Haines,Melissa Hazen,Lauren A Henderson,Assunta Ho,Maria Ibarra,Christi J Inman,Rita Jerath,Khulood Khawaja,Daniel J Kingsbury,Marisa Klein-Gitelman,Khanh Lai,Sivia Lapidus,Clara Lin,Jenny Lin,Deborah R Liptzin,Diana Milojevic,Joy Mombourquette,Karen Onel,Seza Ozen,Maria Perez,Kathryn Phillippi,Sampath Prahalad,Suhas Radhakrishna,Adam Reinhardt,Mona Riskalla,Natalie Rosenwasser,Johannes Roth,Rayfel Schneider,Dieneke Schonenberg-Meinema,Susan Shenoi,Judith A Smith,Hafize Emine Sönmez,Matthew L Stoll,Christopher Towe,Sara O Vargas,Richard K Vehe,Lisa R Young,Jacqueline Yang,Tushar Desai,Raymond Balise,Ying Lu,Lu Tian,Gill Bejerano,Mark M Davis,Purvesh Khatri,Elizabeth D Mellins,Vivian E Saper,Guangbo Chen,Gail H Deutsch,R Paul Guillerman,Johannes Birgmeier,Karthik Jagadeesh,Scott Canna,Grant Schulert,Robin Deterding,Jianpeng Xu,Ann N Leung,Layla Bouzoubaa,Khalid Abulaban,Kevin Baszis,Edward M Behrens,James Birmingham,Alicia Casey,Michal Cidon,Randy Q Cron,Aliva De,Fabrizio De Benedetti,Ian Ferguson,Martha P Fishman,Steven I Goodman,T Brent Graham,Alexei A Grom,Kathleen Haines,Melissa Hazen,Lauren A Henderson,Assunta Ho,Maria Ibarra,Christi J Inman,Rita Jerath,Khulood Khawaja,Daniel J Kingsbury,Marisa Klein-Gitelman,Khanh Lai,Sivia Lapidus,Clara Lin,Jenny Lin,Deborah R Liptzin,Diana Milojevic,Joy Mombourquette,Karen Onel,Seza Ozen,Maria Perez,Kathryn Phillippi,Sampath Prahalad,Suhas Radhakrishna,Adam Reinhardt,Mona Riskalla,Natalie Rosenwasser,Johannes Roth,Rayfel Schneider,Dieneke Schonenberg-Meinema,Susan Shenoi,Judith A Smith,Hafize Emine Sönmez,Matthew L Stoll,Christopher Towe,Sara O Vargas,Richard K Vehe,Lisa R Young,Jacqueline Yang,Tushar Desai,Raymond Balise,Ying Lu,Lu Tian,Gill Bejerano,Mark M Davis,Purvesh Khatri,Elizabeth D Mellins
DOI: https://doi.org/10.1136/annrheumdis-2019-216040
IF: 27.973
2019-09-27
Annals of the Rheumatic Diseases
Abstract:Objective To investigate the characteristics and risk factors of a novel parenchymal lung disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). Methods In a multicentre retrospective study, 61 cases were investigated using physician-reported clinical information and centralised analyses of radiological, pathological and genetic data. Results LD was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the interleukin (IL)-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopaenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes ± ground-glass opacities. The predominant pathology (23 of 36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. The 5-year survival was 42%. Whole exome sequencing (20 of 61) did not identify a novel monogenic defect or likely causal PAP-related or macrophage activation syndrome (MAS)-related mutations. Trisomy 21 and young sJIA onset increased LD risk. Exposure to IL-1 and IL-6 inhibitors (46 of 61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but was not associated with LD features. Conclusions A rare, life-threatening lung disease in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.
rheumatology